Glycopyrrolate topical - Dermira

Drug Profile

Glycopyrrolate topical - Dermira

Alternative Names: DRM-04B; DRM04; Glycopyrronium tosylate; Glycopyrronium tosylate hydrate; Glycopyrronium tosylate monohydrate

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stiefel Laboratories
  • Developer Dermira
  • Class Antiasthmatics; Antispasmodics; Pyrrolidines; Quaternary ammonium compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Hyperhidrosis

Most Recent Events

  • 06 Nov 2017 Preregistration for Hyperhidrosis (In adults, In adolescents) in USA (Topical)
  • 06 Nov 2017 Dermira announces intention to market glycopyrrolate for the treatment of Hyperhidrosis in the second half of 2018
  • 06 Nov 2017 FDA assigns PDUFA action date of 30/06/2018 for glycopyrrolate for Hyperhidrosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top